Newamsterdam Pharma Company N.V. ((NAMS)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
NewAmsterdam Pharma Company N.V. (NAMS) is conducting a Phase 3 study titled A Placebo-controlled, Double-blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib/Ezetimibe Fixed Dose Combination Daily on Coronary Plaque Characteristics in Participants With Atherosclerotic Cardiovascular Disease on Coronary CT Angiography (REMBRANDT Trial). The study aims to assess the impact of a fixed-dose combination of obicetrapib and ezetimibe on coronary plaque and inflammation in patients with high-risk atherosclerotic cardiovascular disease (ASCVD) who are not adequately controlled by their current lipid-modifying therapy.
The intervention being tested is a daily fixed-dose combination of obicetrapib 10 mg and ezetimibe 10 mg, designed to improve coronary plaque characteristics and reduce inflammation in ASCVD patients.
This interventional study is randomized with a parallel assignment model. It employs a quadruple masking approach, meaning that the participant, care provider, investigator, and outcomes assessor are all blinded to the treatment allocation. The primary purpose of the study is prevention.
The study began on February 28, 2024, with a primary completion date yet to be announced. The most recent update was submitted on June 12, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
The outcome of this study could significantly impact NewAmsterdam Pharma’s stock performance, as positive results may enhance investor confidence and market position, especially in the competitive cardiovascular treatment market. Investors should watch for updates as the study progresses.
The REMBRANDT Trial is ongoing, with further details available on the ClinicalTrials portal.